An Australian bio-tech company is developing exosome-based products for disease detection
On Talk Ya Book with Chris Judd, Andrew Chapman from Merchant Funds Management joined us to discuss how an Australian bio-tech company is developing exosome-based products for disease detection.
Andrew and Chris discuss Inoviq (ASX:IIQ), a bio-tech company whose goal is to develop and commercialise a portfolio of diagnostic and exosome-based products for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases.
Merchant Funds Management specialise in small and micro-cap companies listed on the ASX.
Talk Ya Book is presented by Honan Insurance.
